Faron unveils immunotherapy data in myeloid malignancies at EHA. June 15, 2026 Faron Pharmaceuticals (AIM: FARN; First North: FARON) announced a poster presentation highlighting biological evidence from the BEXMAB Phase 1/2 trial validating its first-in-class immunotherapy candidate, bexmarilimab, for myeloid malignancies, at the European Hematology Association (EHA) 2026 Congress, June 11-14, in Stockholm. In a statement, Dr. Mika Kontro, MD, PhD, associate professor at Helsinki University Hospital Comprehensive Cancer Center, and principal investigator of the BEXMAB trial, commented, "These results reinforce the potential of bexmarilimab to deliver clinically meaningful benefit in HR-MDS. A median duration of CR of 16.1 months in frontline patients is an encouraging signal, and the translational data add important biological depth. We are seeing evidence of genuine immune reprogramming in the bone marrow, with recovery of healthy progenitor cells and activation of cytotoxic T cell responses. Together, these findings provide a compelling foundation for the randomized Phase 2b BEXERA trial." Dr. Juho Jalkanen, CEO of Faron, remarked, "The findings presented at EHA 2026 represent a vital milestone in our disciplined generation of evidence for bexmarilimab. The biological evidence of hematological recovery seen with bexmarilimab means that it reduces cancer cells and actively helps a patient's body rebuild its blood-producing system and capacity to fight the disease, providing hope for a durable recovery where options have been historically limited."

Faron Pharmaceuticals held its annual general meeting in Turku, Finland, on 4 May 2026, with 39 shareholders representing 46,850,172 shares and votes. The AGM approved all proposals from the Board of Directors and Shareholder's Nomination Board. The meeting adopted the financial statements and discharged board members and the CEO from liability for 2025. No dividend will be paid, and losses of €27.2 million will be carried forward to the reserve for invested unrestricted equity. The board will comprise six members. Tuomo Pätsi, Marie-Louise Fjällskog, Christine Roth, Colin Bond and Juho Jalkanen were re-elected, whilst George Golumbeski joined as a new member. Annual remuneration for board members remains unchanged at €35,000, with the chair receiving an additional €35,000.

Faron Pharmaceuticals oy: notice of AGM (20260410 AGM notice Faron ENG final). Published on 04/10/2026 at 10:18 am EDT NOTICE OF FARON PHARMACEUTICALS LTD'S ANNUAL GENERAL MEETING Shareholders of Faron Pharmaceuticals Ltd (the "Company") are notified of the Annual General Meeting (the "AGM") to be held on 4 May 2026 at 10:00 a.m. EEST (Finnish time) at Putous auditorium at Vierailukeskus JOKI, 2. floor, Lemminkäisenkatu 12 B, FI-20520 Turku, Finland. The registration of attendees and the distribution of voting slips will commence at the meeting venue at 9:30 a.m. EEST (Finnish time). The Company's Annual Report 2025 is available for review and downloading on the Company's website at https://www.faron.com/. Pursuant to Chapter 5, Section 25 of the Finnish Limited Liability Companies Act, shareholders who are present at the AGM are entitled to request information regarding the matters on the agenda of the AGM. Changes in shareholding occurring after the record date of the AGM do not affect the right to participate in the AGM or the number of votes held by a shareholder. On the date of this notice, 10 April 2026, the total number of shares and votes in the Company is 157,527,889, and the Company holds 41,743,928 treasury shares. The AGM shall be held in Finnish, partially translated into English. Turku, 10 April 2026 FARON PHARMACEUTICALS LTD Board of Directors Appendices Appendix 1: Terms and Conditions of Stock Options 2026 THE NEW SHARES ISSUED IN THE RIGHTS OFFERING WILL NOT BE REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), OR UNDER THE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION OF THE UNITED STATES, AND MAY NOT BE OFFERED, SOLD OR TRANSFERRED, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES EXCEPT PURSUANT TO AN EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN COMPLIANCE WITH ANY APPLICABLE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION OF THE UNITED STATES. Attachments * Original document * Permalink Disclaimer Faron Pharmaceuticals Oyj published this content on April 10, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on April 10, 2026 at 14:17 UTC. (C) Publicnow - 2026